Association of the Tyrosine/Nitrotyrosine pathway with death or ICU admission within 30 days for patients with community acquired pneumonia
Authors:
- Thomas BaumgartnerTBThomas Baumgartner
- Giedré ZurauskaitéGZGiedré Zurauskaité
- Yannick WirzYWYannick Wirz
- Marc MeierMMMarc Meier
- Christian SteuerCSChristian Steuer
- Luca BernasconiLBLuca Bernasconi
- Andreas HuberAHAndreas Huber
- Mirjam Christ-CrainMCMirjam Christ-Crain
- Christoph HenzenCHChristoph Henzen
- Claus HoessCHClaus Hoess
- Robert ThomannRTRobert Thomann
- Werner ZimmerliWerner Zimmerli
Open Access
- 24 August 2018
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 1-8
Abstract
Oxidative stress is a modifiable risk-factor in infection causing damage to human cells. As an adaptive response, cells catabolize Tyrosine to 3-Nitrotyrosine (Tyr-NO2) by nitrosylation. We investigated whether a more efficient reduction in oxidative stress, mirrored by a lowering of Tyrosine, and an increase in Tyr-NO2 and the Tyrosine/Tyr-NO2 ratio was associated with better clinical outcomes in patients with community-acquired pneumonia (CAP). We measured Tyrosine and Tyr-NO2 in CAP patients from a previous randomized Swiss multicenter trial. The primary endpoint was adverse outcome defined as death or ICU admission within 30-days; the secondary endpoint was 6-year mortality. Of 278 included CAP patients, 10.4% experienced an adverse outcome within 30 days and 45.0% died within 6 years. After adjusting for the pneumonia Severity Index [PSI], BMI and comorbidities, Tyrosine nitrosylation was associated with a lower risk for short-term adverse outcome and an adjusted OR of 0.44 (95% CI 0.20 to 0.96, p = 0.039) for Tyr-NO2 and 0.98 (95% CI 0.98 to 0.99, p = 0.043) for the Tyrosine/Tyr-NO2 ratio. There were no significant associations for long-term mortality over six-years for Tyr-NO2 levels (adjusted hazard ratio 0.81, 95% CI 0.60 to 1.11, p = 0.181) and Tyrosine/Tyr-NO2 ratio (adjusted hazard ratio 1.00, 95% CI 0.99 to 1.00, p = 0.216). Tyrosine nitrosylation in our cohort was associated with better clinical outcomes of CAP patients at short-term, but not at long term. Whether therapeutic modulation of the Tyrosine/Tyr-NO2 pathway has beneficial effects should be evaluated in future studies. ISRCTN95122877. Registered 31 July 2006.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_150531)
- Forschungsrat Kantonsspital Aarau (1410.000.058, 1410.000.044)
This publication has 31 references indexed in Scilit:
- Nitrotyrosine Level Was Associated with Mortality in Patients with Acute Kidney InjuryPLOS ONE, 2013
- The missing link between indoleamine 2,3‐dioxygenase mediated antibacterial and immunoregulatory effectsJournal of Cellular and Molecular Medicine, 2009
- The Expanded Biology of SerotoninAnnual Review of Medicine, 2009
- Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trialBMC Health Services Research, 2007
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- Biodegradation of 3-Nitrotyrosine byBurkholderiasp. Strain JS165 andVariovorax paradoxusJS171Applied and Environmental Microbiology, 2006
- Nitrosative stress and pharmacological modulation of heart failureTrends in Pharmacological Sciences, 2005
- Nitric oxide synthases: Roles, tolls, and controlsCell, 1994
- Effect of aging on pulmonary superoxide dismutaseMechanisms of Ageing and Development, 1990
- STUDIES ON INFLAMMATIONJournal of Cell Biology, 1961